Please login to the form below
Verzenio
This page shows the latest Verzenio news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly focuses on 2022 launches as revenues climb by 18%
Diabetes medicine Trulicity (dulaglutide), immunology blockbuster Taltz (ixekizumab), breast cancer therapy Verzenio (abemaciclib) and migraine prevention antibody Emgality (galcanezumab-gnlm) each saw revenues rise by more than 30% year on year.
Latest news
-
FDA approves Eli Lilly’s Verzenio in high risk early breast cancer
Adding Verzenio to endocrine therapy (ET) demonstrated a significant and clinically meaningful reduction in the risk of recurrence. ... Verzenio is the first and only CDK4/6 inhibitor approved for this patient population.
-
Eli Lilly demonstrates Verzenio win in high-risk breast cancer subset at ASCO
Verzenio plus endocrine therapy reduced the risk of patients developing metastatic disease by 39%. ... risk of recurrence with the addition of Verzenio to standard endocrine therapy,” she added.
-
Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales
This increase can be attributed to Lily’s key growth products, including Trulicity, Verzenio, Olumiant, Tyvyt, Emgality, Jardiance, Retevmo, Cyramza and Taltz.
-
Lilly’s Verzenio scores a win in early-stage breast cancer
In the monarchE trial, patients with hormone receptor positive (HR+), HER2-negative high-risk early breast cancer were given Verzenio (abemaciclib) in combination with endocrine therapy. ... The two-year distant relapse-free survival rate was 93.6% in
-
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata
According to NICE, Ibrance now joins two other of its approved drugs – Novartis’ Kisqali (ribociclib) and Lilly’s Verzenio (abemaciclib) - as a treatment option for patients at this stage of the
More from news
Approximately 10 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Sue Mahony to retire as president of Lilly Oncology
Mahony led Lilly Oncology through the integration of ImClone and launched several brands including Verzenio.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
- New Swiss research reveals how Omicron evades the immune system
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
